1122 GMT - AstraZeneca's sales beat and key catalysts for 2025 outshine its core operating profit miss, Barclays analysts says in a note. The British pharma giant's oncology drugs beat sales expectations, driven by lung-cancer drug Tagrisso and breast-cancer treatment Lynparza, Barclays says. However, its core operating profit margin missed company-compiled consensus by 30%, they say. "We see AstraZeneca as having the strongest catalyst path in 2025 of any company in our coverage," the analysts say. Shares are up 5.1% at 116.92 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 06, 2025 06:22 ET (11:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.